CBD Guides

CBDA vs CBD: what’s the difference and which suits you?

By the Honest CBD Co team · 1st August 2026 · Updated 20th August 2026

CBDA is the raw, acidic precursor to CBD. They’re chemically different compounds, they interact with the body in different ways, and neither one is simply better than the other. If you’re shopping in the UK, the sensible question isn’t “which is stronger”, it’s what you’re hoping to help with, how the product was processed, and how much you care about the strength of the evidence behind it.

One thing we’ll say up front, because we’d rather be straight with you than sell you something: we don’t make a CBDA product. Honest CBD Co is a CBD business. This article is here to explain CBDA properly so you can judge the claims you’ll see elsewhere, not to steer you towards a bottle of ours with a CBDA label on it, because there isn’t one.

The Food Standards Agency regulates CBD and CBDA products in the UK under the Novel Food regime, so compliant products should either carry authorisation or sit on the validated applications list. CBDA attracts interest for its anti-inflammatory and anti-nausea mechanisms. CBD has the stronger human clinical evidence base, particularly around anxiety and seizure-related disorders.

At a glance, where each tends to get discussed:

CBDA: anti-inflammatory support (COX-2 pathway), nausea reduction, possibly active at lower doses in animal models
CBD: anxiety relief, seizure research (the strongest human trial data), general wellness
Raw full-spectrum products where both are present: possible entourage benefits, broader cannabinoid profile

How do CBDA and CBD actually compare?
What are CBDA and CBD, and how does decarboxylation change them?
How do CBDA and CBD interact with the body differently?
What does the research actually show about bioavailability and effects?
Are CBDA and CBD safe, and what interactions should you know about?
How to choose CBDA or CBD products in the UK
What do people notice when switching between CBDA and CBD?
How do dosage and administration differ for CBDA and CBD?
Do CBDA and CBD work better together?
Where Honest CBD Co fits in
Key takeaways
Why CBDA deserves more attention than it gets
Sources and further reading

How do CBDA and CBD actually compare?

Feature	CBDA	CBD
Chemical form	Acidic (carries carboxyl group)	Neutral (decarboxylated)
How produced	Raw or cold-processed hemp	Heat or time converts CBDA to CBD
Primary targets	COX-2 inhibition, 5-HT1A serotonin receptors	Endocannabinoid system, TRPV1, broad receptor modulation
Stability	Thermally unstable, degrades with heat or light	Stable across most storage conditions
Typical product types	Raw paste, cold-extracted tinctures	Oils, capsules, isolates, decarboxylated extracts
Evidence strength	Pre-clinical (animal), limited human data	Stronger human clinical data (anxiety, seizures)

What actually matters if you’re buying in the UK:

CBDA shows higher oral bioavailability in animal and limited canine studies, though human pharmacokinetic data are still thin
CBD has the far larger body of human trial evidence
Both can affect CYP3A4 drug metabolism, so check with your GP if you take other medicines
A product that only says “raw” on the front label tells you very little. A seller who can’t tell you what’s actually in the bottle isn’t worth your money

What are CBDA and CBD, and how does decarboxylation change them?

CBDA (cannabidiolic acid) is the compound you find in raw, unprocessed hemp. It carries an extra carboxyl group (a COOH cluster) that makes it more polar and chemically distinct from CBD. Apply heat, whether that’s drying, extraction, vaping or just months on a warm shelf, and that carboxyl group breaks off. CBDA becomes CBD. That reaction is called decarboxylation.

The practical upshot is worth understanding. A raw paste that’s been cold-processed will hold on to more of its CBDA. A standard decarboxylated oil or capsule will be mostly CBD. Neither approach is wrong. They just give you different cannabinoid profiles.

Product types and what they typically contain:

Raw full-spectrum paste: cold-processed, CBDA better preserved, whole-plant extract
Decarboxylated oil or tincture: heat-processed, CBD dominant
Capsules: usually decarboxylated, convenient but CBDA-poor
Isolate: pure CBD, no CBDA and no other cannabinoids

Worth knowing: If CBDA is genuinely what you are after, look for a stated CBDA figure rather than just the word \x{201c}raw\x{201d}. And store anything you’re hoping keeps its CBDA somewhere cool and dark, because thermal instability is real. A sunny windowsill will quietly convert CBDA to CBD over the months.

How do CBDA and CBD interact with the body differently?

The two work through genuinely different pathways, which is why treating them as swappable alternatives misses what’s interesting about them.

CBDA acts indirectly. Its best-studied mechanism is selective inhibition of the COX-2 enzyme, the same target as many non-steroidal anti-inflammatory drugs. It also shows a higher affinity for 5-HT1A serotonin receptors than CBD does, which is thought to sit behind its anti-nausea effects in animal models. What CBDA doesn’t do is bind strongly to CB1 or CB2 receptors.

CBD spreads itself across more targets. It modulates the endocannabinoid system, activates TRPV1 (a pain and temperature receptor), and interacts with adenosine and serotonin pathways. That wider profile is probably why CBD has picked up more human trial data across anxiety, pain and seizure research.

The entourage effect adds another layer. Research published in Nature Scientific Reports found that full-spectrum extracts raise CBDA plasma levels significantly compared with CBDA given on its own, by inhibiting the intestinal BCRP efflux transporter. Cannabinoids such as CBG can block that transporter, which means CBDA sitting in a full-spectrum extract may reach the bloodstream more effectively than CBDA on its own.

What does the research actually show about bioavailability and effects?

Study type	Key finding	Evidence level
Rat pharmacokinetics	CBDA shows higher Cmax and AUC than CBD after oral dosing	Pre-clinical
Beagle PK study	CBDA oral exposure exceeded CBD in full-spectrum and isolate forms	Limited animal (canine)
BCRP mouse study	Full-spectrum extract raised CBDA plasma concentrations versus CBDA alone	Pre-clinical
Human clinical trials	CBD has the stronger evidence base, CBDA human PK data are scarce	Emerging pre-clinical only

The honest reading of that: higher bioavailability in animals is a promising signal, not proof of the same effect in people. Working out a human dose from animal studies isn’t reliable. On current evidence, CBDA looks more like a complement to CBD than a replacement for it, particularly in whole-plant extracts where both are present.

Are CBDA and CBD safe, and what interactions should you know about?

Both are generally well tolerated at typical wellness doses, but there are a couple of real cautions worth knowing.

CBD’s side-effect profile is the better documented of the two. The commonly reported effects are tiredness, some gastrointestinal upset and appetite changes, more often at higher doses. What we know about CBDA’s tolerability comes mostly from animal studies, where it looks well tolerated, but the human safety data are thin.

Key safety points:

Both can affect CYP3A4 and related drug-metabolising enzymes. If you take anticoagulants, antiepileptics or other regular medication, have a word with your GP or pharmacist before you start
Neither CBDA nor CBD is an approved treatment for any medical condition in the UK
UK rules cap controlled cannabinoids at a very low level, and a compliant product should contain no more than 1mg of THC per container

Worth knowing: Cannabinoids and grapefruit juice affect some of the same liver enzymes. If you’ve ever been told to avoid grapefruit with a medicine you take, that’s a good prompt to ask your pharmacist about CBD too.

How to choose CBDA or CBD products in the UK

Deciding between raw CBDA, decarboxylated CBD, or a whole-plant product that contains a mix comes down to a short list of checks.

Know what you’re buying: raw, cold-processed paste holds more CBDA; decarboxylated oils and capsules are CBD-dominant
Be wary of CBDA claims with no number behind them: if a brand sells on CBDA, it is fair to expect a figure to go with it. Reputable sellers can tell you what’s in their products
Storage matters: anything sold on its CBDA content needs cool, dark conditions
Work out the price per mg: it’s the only fair way to compare two bottles, and it exposes a lot of overpriced CBD
Start low: CBDA may be active at lower milligram doses in animal models, but human dosing is genuinely uncertain. Begin low and give it a fair few weeks before you judge it

Where do we sit in that? We don’t sell a CBDA product, and we’re not going to dress one up as one. What we do sell is CBD, made in the UK in small batches. Our Full Spectrum Whole Plant Paste (15% or 30%, in 5ml syringes from £17.99) is the closest thing in our range to a whole-plant extract, and our Full Spectrum CBD Oil (10ml, 10% at £25.99 or 20% at £37.99) keeps the wider cannabinoid profile in a more familiar dropper bottle. We haven’t measured the CBDA in either, so we’re not going to tell you they’re a CBDA product. If preserved CBDA is specifically what you want, buy from someone who can give you a figure for it.

The UK Novel Food regime is also worth keeping in mind: buy from sellers whose products are on the FSA’s validated applications list or who can show you how they comply.

What do people notice when switching between CBDA and CBD?

Accounts of CBDA versus CBD tend to cluster around a few themes. These are personal observations, not clinical outcomes, so treat them as such.

People using a raw paste often describe a different quality of effect compared with a standard decarboxylated oil. Some talk about a gentler onset, which may have more to do with CBDA’s receptor profile than with potency. Others find raw paste suits them better for digestive discomfort or morning queasiness, which lines up with CBDA’s 5-HT1A serotonin receptor activity.

Going the other way, from raw paste to a decarboxylated oil, some people find they need a slightly higher milligram dose to get to the same place. That’s consistent with the animal bioavailability data. Individual responses vary a lot though, and keeping a simple log of dose, timing and effect over a few weeks is still the most practical way to find what works for you.

How do dosage and administration differ for CBDA and CBD?

CBD dosing is on firmer ground because there’s more human evidence behind it. CBDA has no equivalent human reference point. The animal data hint that it may be active at lower doses, but turning that into a human milligram figure isn’t something anyone can do with confidence yet. So the practical advice below is about CBD.

The FSA advises healthy adults to keep CBD intake from food supplements to around 10mg a day. That figure is deliberately precautionary, and it’s worth knowing where it came from: until autumn 2023 the FSA’s own guidance was 70mg a day, and clinical research has used doses running into the hundreds of milligrams. Our honest opinion, after selling CBD since 2018, is that 10mg is out of step with how people actually use it. Most regular users we speak to settle somewhere between 25mg and 100mg or more a day. It isn’t a legal limit and it isn’t a maximum dose.

What we’d actually suggest: start at 10-20mg a day, give it a fair trial of a couple of weeks rather than judging it overnight, then step up gradually until you find the level that does something for you. With our Full Spectrum CBD Capsules that maps neatly onto the strengths: 40mg for starting out, 80mg once you’re taking it regularly, 120mg for experienced users who already know their level. Build up gradually rather than jumping in at the top, and talk to your GP or pharmacist first if you take prescription medication or you’re pregnant or breastfeeding.

Format changes how much reaches your system, too. Oils and pastes held under the tongue for 60-90 seconds tend to absorb faster than capsules, which go through the digestive system first. Capsules win on convenience and on knowing exactly what you’ve taken. For CBDA specifically, oral and sublingual routes keep the compound intact, while anything involving heat, vaping for instance, will decarboxylate CBDA to CBD before it’s absorbed.

Do CBDA and CBD work better together?

Probably, on the pre-clinical evidence. The BCRP transporter research shows that other cannabinoids in a full-spectrum extract can block the intestinal pump that would otherwise cut CBDA absorption, so CBDA reaches higher plasma levels as part of a whole-plant extract than it does alone.

Absorption isn’t the whole story either. Acidic cannabinoids like CBDA appear to bring pharmacological actions that CBD doesn’t replicate: COX-2 inhibition, 5-HT1A activity and possibly PPAR-gamma activation. A raw full-spectrum product captures those alongside CBD’s broader receptor modulation. Whether that adds up to meaningfully better outcomes in people is still an open question, but the mechanistic case for combining them is stronger than the case for either one on its own.

Where Honest CBD Co fits in

We’ll be blunt, because it’s the whole point of the name: if you’ve come here looking for a UK-made CBDA oil, we haven’t got one. We’re a CBD company.

Honest CBD Co is a husband-and-wife business in Bolton. We’ve been trading since 2018, everything we sell is made in the UK in small batches, and we’re online only. That’s the whole operation. We’re rated Excellent on Trustpilot across 732 reviews, and our pricing is deliberately plain: work out the cost per mg and compare us with anyone you like.

Our Full Spectrum Whole Plant Paste and our Full Spectrum CBD Oil are the closest we come to whole-plant options, with the wider cannabinoid profile a full-spectrum extract brings. What we won’t do is put a CBDA claim on them, because we haven’t verified the CBDA content and we’re not prepared to guess in a direction that happens to suit us. If you want CBD from people who’ll tell you what they don’t know, we’re a good fit. If you specifically want CBDA, buy elsewhere and buy from someone who can back the claim.

Key takeaways

CBDA and CBD are chemically distinct cannabinoids with different mechanisms. Raw products that hold on to both have the broadest pre-clinical rationale for combined use, though the human evidence still lags behind.

Point	Details
Chemical difference	CBDA carries an extra carboxyl group. Heat converts it to CBD through decarboxylation.
Evidence gap	CBD has stronger human clinical data. CBDA evidence is largely pre-clinical and animal-based.
Bioavailability signal	Animal studies show CBDA reaching higher oral plasma exposure than CBD, but human data are limited.
UK compliance check	A compliant product should hold no more than 1mg of THC per container and sit on the FSA validated applications list.
Where we stand	We don’t sell a CBDA product. Our full-spectrum oil and whole-plant paste are CBD products, and we make no CBDA claim for them.

Why CBDA deserves more attention than it gets

CBDA has spent years in CBD’s shadow, partly because it’s harder to keep stable and partly because the human trial data simply aren’t there. We find that a bit frustrating, because the mechanistic signals are genuinely interesting. COX-2 inhibition without the gastrointestinal risks of NSAIDs, higher oral bioavailability in animal models, a distinct serotonin receptor profile. That’s a compound worth taking seriously rather than writing off as “pre-CBD”.

We watch the research as it comes out, and we’d be glad to see more of it. But we’re wary of overclaiming, including on our own behalf. The gap between a promising animal study and a solid human trial is wide, and we’d rather you went in with realistic expectations than felt let down. If you do try a CBDA product from someone who sells one, keep a simple record: dose, timing, what you notice. That kind of patient, personal testing is how most people work out what suits them, and we’re happy to talk it through with you either way.

Sources and further reading

CBDA chemistry and decarboxylation (PubMed), covering the carboxyl group structure and the conversion mechanism
CBDA thermal instability and storage (PubMed), behind the storage and labelling guidance above
Beagle pharmacokinetic study, CBDA versus CBD oral bioavailability, 2025 (Frontiers in Veterinary Science), the primary source for the bioavailability data
BCRP efflux and full-spectrum CBDA plasma levels (Nature Scientific Reports), which explains the entourage absorption mechanism
Therapeutic potential of acidic cannabinoids (Journal of Cannabis Research), a review of CBDA pharmacology
Entourage effect and cannabinoid complementarity (PMC), on combined cannabinoid use
Food Standards Agency, CBD Novel Food guidance, for the UK regulatory context

This article is general information only, not medical advice. Consult a qualified health professional or pharmacist for guidance specific to your situation, particularly if you take other medicines.